Unlocking the potential of direct-to-patient as decentralised trials continue to grow
The global healthcare and pharmaceutical industry is frequently faced with having to find new ways of innovating and carrying out its work in order to overcome tragic circumstances that will typically come with a huge human cost.
During the peak of the Covid-19 pandemic this challenge reached new heights, as pharmaceutical firms around the world mobilised the full might of their resources to try and identify, develop, and trial a wide range of vaccines and therapeutics to alleviate the lethal threat posed by the virus.
Read the complete article here